Novel Therapies for Thyroid Autoimmune Diseases

Area of Science:

• Immunology
• Endocrinology
• Molecular Biology

Background:

• The C-X-C chemokine receptor 3 (CXCR3) and its ligands (CXCL10, CXCL9, CXCL11) are involved in the immune pathogenesis of autoimmune thyroid diseases.
• These chemokines are interferon-γ (IFNγ)-dependent and play a role in recruiting Th1 lymphocytes to thyroid tissue, perpetuating autoimmune processes.
• Elevated levels of IFNγ-inducible chemokines are observed in patients with active autoimmune thyroiditis (AT), Graves' disease (GD), and Graves' ophthalmopathy (GO).

Purpose of the Study:

• To review the role of the CXCR3 axis in the immune pathogenesis of AT, GD, and GO.
• To discuss current and potential therapeutic strategies targeting this pathway.

Main Methods:

• Literature review of studies investigating CXCR3, its ligands, and related therapeutic interventions in autoimmune thyroid diseases.
• Analysis of data on chemokine levels in patients with AT, GD, and GO.
• Evaluation of the immunomodulatory effects of agents like PPAR agonists and methimazole on CXCR3 chemokines.

Main Results:

• High levels of IFNγ-inducible chemokines are present in active phases of AT, GD, and GO.
• Peroxisome proliferator-activated receptor (PPAR)γ or -α agonists and methimazole demonstrate immunomodulatory effects on CXCR3 chemokines in these conditions.
• Emerging therapies, including CXCR3 antagonists and CXCL10 blockers, are under investigation for Hashimoto's thyroiditis (HT), GD, and GO.

Conclusions:

• The CXCR3 chemokine system is a significant factor in the pathogenesis of autoimmune thyroid diseases.
• Targeting the CXCR3 pathway holds promise for novel therapeutic approaches.
• Further randomized controlled studies are necessary to validate new treatments like rituximab for GO and generalize findings.